News Results for Oncimmune Holdings (ONC)

Immunodiagnostics group Oncimmune posted a deeper first-half loss amid a rise in R&D and administrative expenses. Pre-tax losses for the six months through May amounted to £9.8 million,...

Immunodiagnostics group Oncimmune welcomed that initiation of a study by Biodesix using the company's test for lung cancer. Biodesix had initiated clinical utility study designed to evaluate the...

Immunodiagnostics group Oncimmune said it had signed a commercial agreement with California-based Cedars-Sinai to provide antibody profiling in Covid-19 samples as biomarkers for the disease....

Immunodiagnostics group Oncimmune said it had won UK government funding to develop a research tool that would predict disease severity and individual therapeutic responses to Covid-19. The funds...

Immunodiagnostics group Oncimmune said it had signed a collaboration agreement with Roche company Genentech. The companies would work to characterise the autoantibody profiles of patients in...

Immunodiagnostics group Oncimmune said it had signed an autoantibody profiling collaboration with 'a leading global biopharmaceutical company' that it did not name. Oncimmune said the company had...

Immunodiagnostics group Oncimmune said the publication of two further study abstracts strengthened evidence that its diagnostic blood test was a cost effective and safe early detection tool for...

Immunodiagnostics group Oncimmune said Roche had exercised an option to increase the scope and value of a cornerstone contract announced by the company back in May. Oncimmune said it had been...

Immunodiagnostics group Oncimmune welcomed the publication of research that had been supported by its technology. The paper was published in Arthritis Research & Therapy1 and demonstrated the...

Immunodiagnostics group Oncimmune said its distributor in Brazil, Valentech International, had obtained marketing authorisation for the company's EarlyCDT Lung lung cancer test. The authorisation...

Dr Adam Hill, Chief Executive Officer, bought 8,481 shares in the company on the 4th June 2020 at a price of 117.90p. The Director now holds 40,913 shares. Story provided by StockMarketWire.com...

Meinhard Schmidt, Chairman, bought 13,000 shares in the company on the 4th June 2020 at a price of 118.50p. The Director now holds 31,000 shares. Story provided by StockMarketWire.com Director...

Timothy Bunting, Non Executive Director, bought 150,000 shares in the company on the 4th June 2020 at a price of 119.20p. The Director now holds 2,956,717 shares. Story provided by...

Immunodiagnostics group Oncimmune said it has signed a further contract with Roche to profile autoantibodies in patient samples collected during cancer immunotherapy trials. It announced that the...

Immunodiagnostics group Oncimmune said it had signed an antigen targeting collaboration to support drug development with a US biopharmaceutical company. The company, which it didn't name, was...

Carsten Schroeder, Non Executive Director, bought 18,000 shares in the company on the 4th May 2020 at a price of 85.00p. The Director now holds 27,000 shares. Story provided by...

Dr Adam Hill, Chief Executive Officer, bought 11,111 shares in the company on the 24th April 2020 at a price of 90.00p. The Director now holds 32,432 shares. Story provided by...

Dr Adam Hill, Chief Executive Officer, bought 21,321 shares in the company on the 1st April 2020 at a price of 46.90p. The Director now holds 21,321 shares. Story provided by StockMarketWire.com...

Meinhard Schmidt, Chairman, bought 18,000 shares in the company on the 24th March 2020 at a price of 49.00p. The Director now holds 18,000 shares. Story provided by StockMarketWire.com Director...

Geoffrey Hamilton-Fairley, Non Executive Director, bought 25,000 shares in the company on the 18th March 2020 at a price of 41.00p. The Director now holds 3,238,070 shares. Story provided by...

Immunodiagnostics group Oncimmune said a UK government body had concluded its blood test for detection of lung cancer could successfully aid early diagnosis in high risk patients. The National...

Immunodiagnostics group Oncimmune said commercial partner Biodesix had commercially launched its lung cancer test in the US. The test assists physicians to identify patients with lung nodules at...

Carsten Schroeder, Non Executive Director, bought 9,000 shares in the company on the 28th February 2020 at a price of 54.10p. The Director now holds 9,000 shares. Story provided by...

Immunodiagnostics focused Oncimmune booked a deeper first-half loss on the back of higher staff and R&D costs. Pre-tax losses for the six months through November amounted to £5.9m, compared to...

finnCap today initiates coverage of Oncimmune Holdings Plc (LON:ONC) with a corporate investment rating and price target of 150p. Story provided by StockMarketWire.com Broker Forecasts data...

Immunodiagnostics group Oncimmune said it had drawn down the second tranche of its previously announced credit facility of €8.5m with IPF Management. Oncimmune drew down an initial €5.0m on...

Immunodiagnostics group Oncimmune said it had completed a strategic commercialisation agreement with Biodesix. The pact involved the company's arlyCDT Lung cancer detection technology for use in...

Immunodiagnostics group Oncimmune said it had secured a new €8.5m credit facility from IPF Management. Oncimmune said it would immediately draw down an initial €5m with the remaining €3.5m to be...

Oncimmune Holdings said it had presented positive study data at an industry conference in Barcelona. The data were presented by professor Frank Sullivan, the chief investigator on a trial of the...

Immunodiagnostics group Oncimmune Holdings said that its existing distributor in Spain and Portugal had signed an agreement with Spanish private healthcare company Vithas Group. The agreement...

Immunodiagnostics group Oncimmune Holdings said it was confident of being able to generate 'material profitable revenues', thanks to several business developments. The company had earlier this...

Immunodiagnostics group Oncimmune Holdings said it had recorded positive results from a study in Scotland of its early lung-cancer detection technology. The study recruited 12,210 patients, each...

Oncimmune Holdings said its distributor for Israel, Best Medical Opinion, had received regulatory approval for the sale of the company's lung-cancer screening product. On an age standardised...

Oncimmune, a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, and its partner, Genostics Company, have...

Cancer diagnostics group Oncimmune Holdings said it had signed an exclusive agreement for the distribution of its lung cancer test kit in Portugal with Sabartech, its existing distributor in...

Oncimmune Holdings said its distributor in Columbia, Valentech International, had obtained regulatory approval for the sale of its lung cancer diagnostics product. Oncimmune had an existing...

Immunodiagnostics group Oncimmune Holdings said its Spanish distributor, Sabartech, hade signed a new supply agreement with Quironsalud. The agreement would involve Oncimmune's EarlyCDT-Lung...

Cancer diagnostics group Oncimmune Holdings said it had acquired Protagen Diagnostics for up to £4.1m. The deal would be funded by the allotment of up to around 2.6m Oncimmune shares 156p per...

Immunodiagnostics system supplier Oncimmune Holdings said its annual losses deepened as it increased R&D spending. Pre-tax losses for the year through November amounted to £3.9m, compared to...

Immunodiagnostics group Oncimmune Holdings posted a deeper annual loss and cut its revenue expectations for the current year due to the collapse of talks with a potential partner. Pre-tax losses...

Cancer diagnostics group Oncimmune Holdings said it had signed new distribution agreements for its lung test product in Spain and India but had another agreement in Hong Kong terminated. The...

Cancer diagnostics group Oncimmune Holdings said founder Geoffrey Hamilton-Fairley would step down from October and take up the newly-created position of vice chairman. He would be replaced by...

Cancer detection company Oncimmune Holdings said it expected its revenue for the year through March to be in line with market expectations, while its expectations for operating costs and its cash...

Cancer detection group Oncimmune Holdings said it had received the final £3m tranche from a £10m equity subscription provided by Genostics Company. The £10m equity investment in Oncimmune was...

Bryan Garnier today reaffirms its buy investment rating on Oncimmune Holdings Plc (LON:ONC) and raised its price target to 168p (from 154p). Story provided by StockMarketWire.com Broker Forecasts...

Oncimmune reported a pretax loss to £2.8m for the six months to 30 November 2017, from a year-earlier loss of £2.5m while revenue for the period was just £77,000, down from £114,000. The wider...

Cancer detection group Oncimmune Holdings said the University of Nottingham, from which it was spun out, had cut its holding in the company. The university sold 4,317,287 shares and would remain a...

Cancer detection company Oncimmune Holdings said it had entered into a licence agreement and completed a £7m equity subscription with Genostics Company. The subscription marked the first tranche...

Cancer-detection company Oncimmune said it had signed a new distribution agreement for Turkey. The deal brought the total number of agreements in Europe and the Asia Pacific region to 12, with...

Berenberg today initiates coverage of Oncimmune Holdings Plc (LON:ONC) with a buy investment rating and price target of 169p. Story provided by StockMarketWire.com

Oncimmune Holdings has appointed Annalisa Jenkins as a new non-executive director. Jenkins was previously chief executive of Dimension Therapeutics, a gene therapy company focused on developing...

Oncimmune Holdings has signed a framework distribution agreement for an exclusive licence with Genostics Company, a Hong Kong registered group that is part of China-based Gene Group. The agreement...

Oncimmune, an early cancer detection company, has validated its EarlyCDT-Liver test on schedule. A commercial test will be available on time from the first half of 2018. The EarlyCDT-Liver test...

Oncimmune Holdings said it will issue shares in a placing following confirmation of their status by the tax office. Consequently, the 833,333 shsres that were conditionally placed as part of the...

Oncimmune posted a narrower annual loss at it continues to develop and market its early cancer-detection technology. The company booked a net loss of £4.8m, narrowing from loss of £8.4m in the...

Oncimmune has signed an exclusive agreement for the distribution of its EarlyCDT lung test in Poland with local group SmartGene. The agreement allows for the sale of the CE marked product as a...

Oncimmune Holdings has raised a total of approximately £5.0m (before expenses) by means of a conditional placing with new and existing investors of 4,166,667 Placing Shares at a price of 120p per...

Oncimmunce Holdings, an early detection of cancer company, on Tuesday announced three distribution agreements worth £500,000. These agreements are for its EarlyCDT- Lung test with LabLab ApS,...

Oncimmune Holdings announced the signing of two further distribution agreements for its EarlyCDT-Lung test kit in Taiwan and Hong Kong, alongside a business update at the end of its first full...

Story provided by StockMarketWire.com

Oncimmune Holdings has obtained the CE mark for EarlyCDT-Lung test in an ELISA kit format. EarlyCDT-Lung is a simple autoantibody blood test that can detect lung cancer up to four years earlier...

Oncimmune Holdings has signed two new exclusive distribution agreements for its EarlyCDT-Lung test with Best Medical Opinion and Dow Biomedica/Biodiscovery in Israel and Korea respectively. The...

Story provided by StockMarketWire.com

Oncimmune has more than doubled its H1 pretax loss to £2.5m, from a year-earlier loss of £1.1m. Revenue was just £114,000, from £272,000. Administrative and R&D expenses were a big part of the...

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Oncimmune Holdings has obtained the CE mark for the reagents used in EarlyCDT-Lung, an autoantibody blood test that can detect cancer up to four years earlier than other methods. The CE mark...

Story provided by StockMarketWire.com

Oncimmune Holdings has signed research agreements with Egybiotech, a private research company with a broad research portfolio in the areas of cancer research, and Aarhus University Hospital...

Story provided by StockMarketWire.com

Oncimmune Holdings chief financial officer and director Bob Page died unexpectedly on Friday from natural causes. The company said its sympathies are with his family. All of his responsibilities...

Oncimmune Holdings has entered into three further distribution agreements in the US for its EarlyCDT-Lung test. The three agreements have been signed with national and regional distributors and...

Story provided by StockMarketWire.com